Purpose of Review: Many therapeutic advances for relapsing-remitting multiple sclerosis (MS) have occurred in the past 25 years. Although similar advances in disease-modifying therapies have not been realized in progressive MS, many symptomatic therapeutic strategies can benefit patients with progressive MS. Few guidelines exist for management of patients with progressive MS. Recent Findings: The classification of progressive MS was revised in 2013 to include a description of inflammatory disease activity determined by clinical relapses or imaging findings. Developing knowledge about the pathogenesis of progressive MS and the role of comorbidities in modifying the disease course has implications for the clinical management of patients with progressive MS as well as for clinical trial design. Current and upcoming clinical trials will assess a wide range of interventions, including immunomodulatory agents, putative neuroprotective molecules, stem cell therapy, nutrition, and rehabilitation techniques. Summary: None of the therapies currently approved for use in relapsingremitting MS have been shown to slow the gradual progression of disability that occurs in the absence of recent relapses or changes in MRI. A multidisciplinary approach is needed to address the many symptoms that impact quality of life for patients with progressive MS. Continuum (Minneap Minn) 2016;22(3):785-798.
INTRODUCTION
Multiple sclerosis (MS) is a chronic disorder of the central nervous system that typically presents in the third to fifth decades of life. The symptoms are variable, and the long-term course is often difficult to predict. The 1996 US National Multiple Sclerosis Society (NMSS) Advisory Committee on Clinical Trials in Multiple Sclerosis defined four clinical subtypes of MS: relapsingremitting, secondary progressive, primary progressive, and progressive relapsing. 1 In 2013, the International MS Phenotype Group revised these criteria to separate active inflammation (ie, clinical relapses, new or active lesions on MRI) from gradual insidious clinical progression ( Figure 5-1 ). 2 MS is now classified by these two charac-teristics in parallel instead of the separate distinct relapsing-remitting MS versus secondary progressive MS. Additionally, the progressive-relapsing MS category was eliminated from general use. These modifications recognize the variability in disease course within each subtype as well as the similarities between groups. This article discusses an approach to the management of patients across the spectrum of progressive MS and reviews the evidence available to guide management recommendations.
progressive MS and secondary progressive MS. A diagnosis of secondary progressive MS requires a history of at least one clinical relapse and then at least 6 to 12 months of continuous disability progression that is independent of clinical relapses. No clear clinical criteria exist to determine when a patient transitions from relapsingremitting MS to secondary progressive MS. On the other hand, the criteria for diagnosis of primary progressive MS are well defined. The 2010 criteria for diagnosis of primary progressive MS specify that a combination of 1 year of disease progression (prospective or retrospective) plus MRI or CSF findings as outlined in Table 5 -1 must be present (Case 5-1). 3 Superimposed relapses and gadolinium-enhancing lesions can occur in both types of progressive MS. Table 5 -2 compares the characteristics of secondary progressive MS and primary progressive MS.
As in patients with secondary progressive MS, the average age at the time of primary progressive MS diagnosis is in the fifth to sixth decades of life. Unlike secondary progressive MS, males seem to develop primary progressive MS as frequently as females. 4 The rate of disability progression from the onset of progressive disease is similar for primary progressive and secondary progressive MS, although the course of primary progressive MS is more variable. 5, 6 MRI characteristics for primary progressive MS and secondary progressive MS are comparable, although patients with primary progressive MS generally have more diffuse brain lesions and more spinal cord lesions when compared with patients with relapsing-remitting MS and secondary progressive MS. 5 Athough confluent T2-hyperintense lesions, the presence of T1-hypointense lesions, and brain volume loss are frequently seen in patients with progressive MS, these findings alone do not distinguish patients with a relapsing versus a progressive course.
DIFFERENTIAL DIAGNOSIS
Gradually worsening neurologic function in a patient with MS warrants consideration of other explanations, even in patients with established MS. For example, cervical spondylosis or vitamin B 12 deficiency may contribute to worsening sensory abnormalities or gait impairment. In addition, many conditions can mimic primary progressive MS, which most often presents as a gradually worsening myelopathy. A search for alternative diagnoses should be considered prior to confirmation of primary progressive MS or secondary progressive MS ( Table 5-3) .
PATHOLOGY OF PROGRESSIVE MULTIPLE SCLEROSIS
All phenotypes of MS share the following pathologic findings: inflammation, demyelination, remyelination, axonal loss, and glial scar formation. 7Y9 It has been suggested that progressive forms of MS largely represent a neurodegenerative process with comparably little of the infiltrative inflammation that is pronounced in relapsing-remitting MS. Unlike relapsing-remitting MS, the inflammation in secondary progressive 
Case 5-1
A 35-year-old man presented because of a 2-year history of frequent tripping with his right foot. He had no numbness or tingling, but his entire right leg felt stiff upon awakening in the morning or after prolonged sitting. His neurologic examination revealed moderate spasticity in the knee extensors and ankle plantar flexors on the right. Mild spasticity was present in the left lower extremity. In the right lower extremity, power in the hip flexor was 4/5, knee flexor 4+/5, and ankle dorsiflexor 4/5. Left lower extremity strength was normal. His gait was slow (timed 25-foot walk: 14.4 seconds [normal time approximately 4 seconds]) with short steps, slight circumduction on the right, and poor toe clearance on the right. Vibration and proprioception were impaired in the right lower extremity, with no reproducible sensory level to pinprick. Reflexes were normal in the upper extremities and hyperactive in the lower extremities, right more than left. Sustained clonus was present at the right ankle. Plantar response was extensor bilaterally. His brain MRI ( Figure 5 -2) showed multiple fluid-attenuated inversion recovery (FLAIR) hyperintense periventricular lesions and one lesion that enhanced with gadolinium on T1-weighted imaging. Cervical spine MRI showed multiple short-segment T2/short tau inversion recovery (STIR) hyperintense lesions. CSF analysis revealed three nucleated cells (98% lymphocytes), normal glucose and protein, IgG index 1.01 (upper limit of normal = 0.61), and eight oligoclonal bands in the CSF with 0 in the serum (upper limit of normal = 1). All other laboratory tests were normal. He was diagnosed with primary progressive multiple sclerosis and chose to enroll in a clinical trial.
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Comment. Progressive gait impairment is the most common presentation of primary progressive multiple sclerosis. Initial misdiagnosis is also common. Several features of this patient's presentation suggest that he may benefit from disease-modifying therapy: young age, recent disability progression, and presence of gadolinium-enhancing lesions. Management of spastic myelopathy will also be important to improve his current functioning. MS and primary progressive MS appears to be less robust and is usually dissociated from breakdown in the blood-brain barrier. 9,10 Cortical demyelination is present in relapsing and progressive forms of MS but may be more prominent in progressive MS. 9 Axonal loss and decreased brain volume is present in patients with early relapsing-remitting MS but is more pronounced in patients with progressive disability. 8 Several mechanisms have been proposed to explain the underlying neurodegeneration of progressive MS. 8, 9 It is hypothesized that progressive disability occurs when a patient reaches a threshold of accumulated damage for which compensation is no longer possible (ie, exhaustion of functional reserve). Potential underlying mechanisms include mitochondrial injury related to prolonged oxidative stress, brain iron accumulation, and altered expression of ion channels that may amplify neurodegeneration. 9 Another hypothesis is that MS is a primary neurodegenerative disease with a superimposed inflammatory process that causes further destruction. 8 
ROLE OF DISEASE-MODIFYING THERAPY
The uncertainties regarding the pathogenesis of progressive MS and the timing of transition to a progressive 25 and other immunosuppressive agents such as methotrexate 26 did not show an impact on disease course. Only the European interferon beta-1b trial showed delayed disability progression, while a similar North American trial was negative. 13 It seems clear that peripheral immune modulation alone is not sufficient to alter the course of progressive MS. Some researchers have proposed that inflammation in progressive MS is compartmentalized and thus not easily modified by systemic immunemodulating therapy, although this has yet to be demonstrated. Recent recommendations from the American Academy of Neurology included advice against using interferon beta or glatiramer acetate for patients with disability from progressive nonrelapsing forms of MS. 27 Although this recommendation seems appropriate for patients with untreated progressive MS without evidence for active inflammation, its application to patients in whom active inflammation stopped while taking disease-modifying therapy is probably inappropriate, since we currently are unable to identify those patients who do not have active inflammation because they are taking disease-modifying therapy. At this time, no consensus guidelines exist regarding switching or discontinuation of disease-modifying therapy for patients with progressive MS. A 2011 survey of practice patterns among neurologists (42% academic, 58% community) treating patients with progressive MS revealed variable approaches to the use of disease-modifying therapy for primary progressive MS and secondary progressive MS. Ninety-five percent of responders would switch therapy for a patient with secondary progressive MS with MRI activity and gradual progression. Only 60% felt that disability progression alone was enough to constitute a treatment failure. A small majority (56%) of respondents would start disease-modifying therapy in a patient with primary progressive MS, but 85% would start therapy in the same patient if gadolinium-enhancing lesions were present. 28 In previous clinical trials of progressive MS, some subgroups appeared to benefit from immune-modulating therapies. Characteristics of those patients included younger age, more recent disability progression, recent relapse, and MRI activity. 12, 21, 22 A clinical relapse or MRI activity (ie, new T2 lesions or gadolinium-enhancing lesions) in a patient with progressive MS warrants consideration of a change in MS immune-modulating therapy (including initiation of therapy in a patient who is not currently receiving immune-modulating therapy). A change in therapy when gradually progressive disability occurs in the absence of these inflammatory markers is unlikely to alter the gradually progressive course of progressive MS. Patients should be advised that no evidence exists to guide such changes and no currently approved therapy is expected to restore function.
The risks of escalating diseasemodifying therapy, such as the risk of progressive multifocal leukoencephalopathy, should be discussed frankly with patients who seek to change therapy when potential benefit is thought to be low. As described earlier, screening for other conditions that could contribute to disability progression would be prudent. Treatment should include management of current symptoms, rehabilitation strategies, and identification of needed resources (Case 5-2).
Evidence guiding discontinuation of disease-modifying therapy is sparse. The decision to stop therapy should not be solely guided by age or level of disability. In general, discontinuation of disease-modifying therapy should be considered if the cost, side effects, or other burden of treatment outweighs the perceived benefits (Case 5-3). For more information on discontinuing disease-modifying therapies, refer to the article ''Switching or Discontinuing Disease-Modifying Therapies for Multiple Sclerosis'' by Aaron E. Miller, MD, FAAN, 29 radiographic monitoring should continue after therapy has been stopped.
BEYOND IMMUNE-MODULATING THERAPY
As with relapsing-remitting MS, treatment of progressive MS should not be limited to just immune-modulating therapy. None of the currently approved therapies have been shown to repair preexisting damage or to reverse the persistent symptoms often present in persons with MS. Patients with progressive MS often have complex care needs that are best managed by a multidisciplinary team. 30 Figure 5-3 shows the au-thors' approach to management of patients with progressive MS. 
Case 5-2
A 50-year-old woman with no other medical problems was diagnosed with relapsing-remitting multiple sclerosis (MS) at age 40. Despite treatment with an injectable therapy for 7 years followed by an oral disease-modifying therapy for 3 years, she developed severe myelitis with paraplegia and bladder and bowel incontinence. She received 5 days of IV methylprednisolone and a course of plasma exchange (five exchanges of 1.5 liters) with no immediate improvement. She was nonambulatory upon discharge to acute rehabilitation. Her disease-modifying therapy was changed to natalizumab. Six months after her myelitis episode, she still had residual sensory and motor deficits but could walk with a cane. Although she had no further relapses or new lesions on MRI, she reported gradual worsening of spastic paraparesis and required a rollator for safe ambulation. She reported persistent tightness and heaviness in both arms as well as frequent urinary incontinence. MRI of the brain, cervical spine, and thoracic spine repeated after 24 months of natalizumab showed no new lesions when compared to her studies before starting natalizumab. Moderate cervical spondylosis was present but no cord compression was seen. Laboratory testing for metabolic causes of myelopathy was normal. She inquired about changing her disease-modifying therapy because of her progressive walking difficulties.
Comment. This patient had a very active relapsing-remitting MS disease course, followed by evolution into secondary progressive MS without evidence for active inflammation. A significant decline in function or change in symptoms in the absence of relapse warrants consideration of other etiologies, including compressive myelopathy. After other etiologies are excluded, the management should focus on management of the symptoms of progressive myelopathy. In the absence of active inflammation in this patient, it is unlikely that changing to another immune-modulating therapy will be effective in slowing her gradually progressive myelopathy. Instead, management should focus on her current symptoms, rehabilitation strategies, adjustment to the diagnosis of progressive MS, workplace accommodations, and the potential need for other resources.
Modifications in Multiple Sclerosis'' by Patricia K. Coyle, MD, FAAN, 32 in this issue of Continuum.
Rehabilitation techniques are a cornerstone of comprehensive care in progressive MS. Occupational therapy may be helpful in addressing decreased upper extremity function, cognitive impairment, and energy conservation techniques. Physical therapy may include lower extremity strengthening, gait evaluation and retraining, assessment for orthotics, development of a home exercise program, and evaluation of functional capacity for disability assessment. Speech therapists can evaluate and manage language, speech, and swallowing impairment. Physiatrists may offer comprehensive rehabilitative evaluation and management, including botulinum toxin injec-tions, intrathecal baclofen therapy, and other interventions.
Management of gait disorders common in progressive MS often combines rehabilitation strategies, assistive devices, and symptomatic medications. Dalfampridine, an extended-release formulation of the potassium channel blocker 4-aminopyridine, has been shown to improve walking speed in some patients with MS. Approximately 35% to 43% of subjects in two phase 3 randomized controlled trials demonstrated a clinically relevant improvement on the timed 25-foot walk test with dalfampridine 10 mg extendedrelease tablets taken every 12 hours. 33 Response to treatment appears to be independent of the disease course, baseline walking speed, or baseline Expanded Disability Status Scale (EDSS) KEY POINT h Rehabilitation techniques are a cornerstone of comprehensive care in progressive multiple sclerosis.
Case 5-3
A 66-year-old woman with hypertension and osteoporosis was diagnosed with relapsing-remitting multiple sclerosis (MS) 25 years earlier. Despite treatment with interferon beta for the past 15 years, she developed a progressive myelopathy over the past 8 years and now had secondary progressive MS without relapses or new lesions on MRI. Her cognitive function gradually declined over the past 10 years to the point that she had required total assistance with activities of daily living for the past several years. Her daughter reported that her wandering and agitation improved after starting adult daycare and improving her sleep. Her other medical conditions were well managed by her primary care physician, and age-appropriate screenings and immunizations were up-to-date. The daughter stated that her mother slept excessively, was depressed, and did not eat at all on the day following her interferon injection. Because of changes in her Medicare plan, the family was now responsible for $3000 of medication costs before the remainder was covered. The daughter asked if her mother's interferon therapy was necessary.
Comment. This case illustrates a scenario in which discontinuation of immune-modulating therapy would be favored. This patient has secondary progressive MS and dementia, and has significant side effects and out-of-pocket expense for her immune-modulating therapy. Because of her age and history of disease stability, she may no longer need an MS immune-modulating therapy. Additionally, interferon may be contributing to her sleep disruption, depression, and anorexia. It would be appropriate to discontinue immune-modulating therapy and follow clinically and with imaging to monitor for reactivation of MS inflammation. score. 33 Although the improvement of walking speed is the sole approved indication for use in the United States, other proposed effects of dalfampridine include improved performance in walking endurance measured by the 6-minute walk test, 34, 35 improvement of internuclear ophthalmoparesis, 36 and improved manual dexterity. 35 Mod-erate to severe renal impairment (creatinine clearance of 50 mL/min or lower) and a personal history of seizure are contraindications to the use of dalfampridine.
Review, discussion, prevention, and treatment of other medical comorbidities are important in progressive MS. numbers of comorbidities. 37 The presence of comorbid health conditions or habits can also impact treatment decisions as well as affect disability progression and disease severity. 38Y41 Comorbid conditions of particular concern include smoking, vitamin D deficiency, obesity, hypertension, hyperlipidemia, sleep disorders, osteoporosis, osteoarthritis, depression, anxiety, and thyroid disease. 38, 39 Both smoking and vitamin D deficiency have been associated with disability progression in MS. 40, 41 Routine health maintenance visits with a primary care provider should be encouraged. Education and social needs change as progressive disability causes limitations in performing activities of daily living, reduced or loss of driving ability, loss of employment, and changing family roles. Education and support should not be limited to patients with MS but should also include family members and caregivers. Psychologists and social workers should be consulted where needed.
Quality of life decreases with increasing

FUTURE DIRECTIONS
Our incomplete understanding of the pathophysiology of progressive MS presents a significant challenge in developing effective therapies for this 
CONCLUSION
While many new treatments for relapsing-remitting MS have been developed in the past 10 to 20 years, advances in management of progressive MS lag far behind. While no consensus exists on the use of immune-modulating therapies for patients with progressive MS, the revised diagnostic classification may help identify patients likely to benefit from these treatments. Furthermore, patients with progressive MS typically have therapeutic needs beyond use of immune-modulating therapy. A multidisciplinary approach is often needed to address these treatment needs. Ongoing research may inform best practices for symptomatic management as well as use of neuroprotective agents, repair-promoting agents, and disease-modifying therapies.
